The histopathological examination of a prostate biopsy is the basis of prostate cancer diagnostics.
Prostate cancer grade and extent of cancer in the diagnostic biopsy are important determinants of patient management. Quality of the prostate biopsy and its processing may influence the outcome of the histopathological evaluation. Further, an unambiguous and concise pathology reporting is essential for an appropriate clinical decision process. Since our initial report in 2003, there have been several practice changes, including the increased uptake of follow-up biopsies of patients who are under active surveillance, increasingly taken under guidance of MRI, or who underwent a prostate-sparing therapy. Therefore, we investigated the literature on the current pathology practices and recommendations with regard to prostate biopsy processing and reporting, both at initial diagnosis and in the context of follow-up biopsies in order to update our guidelines on the optimal processing and reporting of prostate biopsies.
Written by:
Van der Kwast T, Bubendorf L, Mazerolles C, Raspollini MR, Van Leenders GJ, Pihl CG, Kujala P. Are you the author?
Department of Pathology, Princess Margaret Cancer Center, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, M5G 2C4, Canada.
Reference: Virchows Arch. 2013 Sep;463(3):367-77.
doi: 10.1007/s00428-013-1466-5
PubMed Abstract
PMID: 23918245
UroToday.com Prostate Cancer Section
